| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8816407 | Schizophrenia Research: Cognition | 2018 | 9 Pages |
Abstract
The results from this trial highlight the therapeutic effects of tDCS for treatment of persistent symptoms in schizophrenia, with reduction of negative symptoms. We were not able to confirm the superiority of active tDCS over sham to improve working memory performance. Larger sample size studies are needed to confirm these findings.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
J.S. Gomes, A.P. Trevizol, D.V. Ducos, A. Gadelha, B.B. Ortiz, A.O. Fonseca, H.T. Akiba, C.C. Azevedo, L.S.P. Guimaraes, P. Shiozawa, Q. Cordeiro, A. Lacerda, A.M. Dias,